Free Trial
NASDAQ:BIOA

BioAge Labs Q2 2025 Earnings Results & Report

BioAge Labs logo
$5.65 -0.22 (-3.75%)
Closing price 04:00 PM Eastern
Extended Trading
$5.70 +0.05 (+0.88%)
As of 04:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioAge Labs missed analyst earnings expectations in its Q2 2025 results, released August 6, 2025. The company reported EPS of -$0.60 versus the -$0.56 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
After Market Closes

BioAge Labs EPS Results

Actual EPS
-$0.60
Consensus EPS
-$0.56
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

BioAge Labs Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

BioAge Labs Q2 2025 Earnings FAQ

BioAge Labs (NASDAQ:BIOA) reported earnings of -$0.60 per share for Q2 2025, missing the consensus estimate of -$0.56. The report was announced on Wednesday, August 6, 2025.

BioAge Labs Earnings Headlines

BTIG Research Reaffirms Buy Rating for BioAge Labs (NASDAQ:BIOA)
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More BioAge Labs Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAge Labs? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAge Labs and other key companies, straight to your email.

About BioAge Labs

BioAge Labs (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment.

The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.

Founded in 2015, BioAge is headquartered in Richmond, California. Co-founder Kristen Fortney, Ph.D., serves as the company’s chief executive officer.

View BioAge Labs Profile